Accendra Health (ACH)
NYSE:ACH
Want to see ACH full AI Analyst Report?
ACH Stock Chart & Stats
$2.57
--
Market closed
$2.57
--
Day’s Range― - ―
52-Week Range$1.84 - $9.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.12M
Market Cap
$217.50M
Enterprise Value$2.05B
Total Cash (Recent Filing)$336.88M
Total Debt (Recent Filing)$2.17B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jul 31, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.05
Shares Outstanding76,583,700
10 Day Avg. Volume949,424
30 Day Avg. Volume1,122,390
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.47
Price to Sales (P/S)0.08
P/FCF Ratio-0.74
Enterprise Value/Market Cap9.43
Enterprise Value/Revenue0.76
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda5.96
Forecast
1Y Price Target
$4.44Price Target Upside72.67% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.7
Revenue Forecast (FY)$2.59B
Bulls Say, Bears Say
Bulls Say
Balance‑sheet Optimization And Extended MaturitiesExtending maturities, adding a $300M committed revolver and lender support to de‑lever up to ~$115M materially reduces near‑term refinancing risk. A longer debt life (~5.5 years) gives management runway to execute operations and structural margin programs without immediate cash‑flow pressure.
Stand‑alone Focus With Structural Margin TransformationThe strategic separation to a pure‑play home‑based care model and reported structural gross/EBITDA margin expansion indicate improved unit economics and clearer strategic priorities. Higher recurring service margins and focused product mix support sustainable operating leverage as scale and execution improve.
Solid Near‑term Liquidity And Covenant ComplianceHaving >$300M cash plus committed revolver capacity and covenant compliance provides immediate financial flexibility to fund operations and complete refinancing. This liquidity buffer supports execution of cost and collection initiatives and lowers short‑term default risk while longer‑term fixes are implemented.
Bears Say
Sharp Revenue Contraction And Large Net LossesA ~42% TTM revenue decline and outsized net losses reflect structural demand or contract disruptions and drive sustained earnings volatility. Negative margins undermine retained earnings, weaken credit metrics, and constrain reinvestment capacity, raising long‑term viability risks if recovery stalls.
Persistent Negative Operating And Free Cash FlowA sustained shift to negative operating and free cash flow forces reliance on external financing, elevates refinancing needs, and limits the company’s ability to self‑fund growth or absorb shocks. Over months this pressure constrains strategic options and increases vulnerability to rising rates.
Higher Expected Interest Expense And Refinancing UncertaintyAn incremental ~$40M of annualized cash interest materially reduces future free cash flow and slows de‑leveraging even after maturities are extended. If final terms are less favorable or execution slips, higher debt service will persistently pressure cash generation and investment capacity.
Accendra Health News
ACH FAQ
What was Accendra Health’s price range in the past 12 months?
Accendra Health lowest stock price was $1.84 and its highest was $9.55 in the past 12 months.
What is Accendra Health’s market cap?
Accendra Health’s market cap is $217.50M.
When is Accendra Health’s upcoming earnings report date?
Accendra Health’s upcoming earnings report date is Jul 31, 2026 which is in 59 days.
How were Accendra Health’s earnings last quarter?
Accendra Health released its earnings results on May 11, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.058.
Is Accendra Health overvalued?
According to Wall Street analysts Accendra Health’s price is currently Undervalued.
Does Accendra Health pay dividends?
Accendra Health does not currently pay dividends.
What is Accendra Health’s EPS estimate?
Accendra Health’s EPS estimate is -0.08.
How many shares outstanding does Accendra Health have?
Accendra Health has 76,583,700 shares outstanding.
What happened to Accendra Health’s price movement after its last earnings report?
Accendra Health reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went up 8.659%.
Which hedge fund is a major shareholder of Accendra Health?
Currently, no hedge funds are holding shares in ACH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Accendra Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.44 (72.67% Upside)
$4.44 (72.67% Upside)
Blogger Sentiment
Bullish
ACH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 635.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.19%
12-Months-Change
Fundamentals
Return on Equity
264.54%
Trailing 12-Months
Asset Growth
-50.25%
Trailing 12-Months
Company Description
Accendra Health
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. The company operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment also supplies a range of other home medical equipment; and patient care products, including ostomy, wound care, urology, and incontinence and other products and services. The company serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Accendra Health, Inc. was formerly known as Owens & Minor, Inc. and changed its name Accendra Health, Inc. in December 2025. The company was founded in 1882 and is based in Glen Allen, Virginia.
ACH Company Deck
ACH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong strategic and financial progress — notably the successful separation, margin transformation, balance sheet optimization commitments, $82M equipment sale and $52M one‑time gain, and operational wins in sleep therapy — while also acknowledging meaningful near‑term pressures: a 6.8% revenue decline, collection and cost headwinds, slightly negative free cash flow in Q1, and an expected ~ $40M annualized increase in cash interest post‑refinancing. Management emphasized that underlying revenue (ex‑large payor) was roughly +1% and that debt reduction and cost‑savings remain priorities, framing the near‑term drawbacks as manageable steps in service of a stronger long‑term standalone profile.View all ACH earnings summariesACH Stock 12 Month Forecast
Average Price Target
$4.44
▲(72.67% Upside)
Ownership Overview
20.71% Insiders
19.79% Mutual Funds
27.78% Other Institutional Investors
17.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---